What is the official website of FUJIFILM Pharmaceuticals U.S.A., Inc. ?

The official website of FUJIFILM Pharmaceuticals U.S.A., Inc. is https://www.fujifilmpharma.com/?utm_source=LinkedIn&utm_medium=company_page&utm_campaign=visit_website.

What is FUJIFILM Pharmaceuticals U.S.A., Inc.'s cybersecurity risk score?

FUJIFILM Pharmaceuticals U.S.A., Inc. has an AI-generated cybersecurity risk score of 750 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has FUJIFILM Pharmaceuticals U.S.A., Inc. experienced?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has FUJIFILM Pharmaceuticals U.S.A., Inc. been affected by any supply chain cyber incidents ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have SOC 2 Type 1 certification ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. is not certified under SOC 2 Type 1.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have SOC 2 Type 2 certification ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. does not hold a SOC 2 Type 2 certification.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. comply with GDPR ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. is not listed as GDPR compliant.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have PCI DSS certification ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. does not currently maintain PCI DSS compliance.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. comply with HIPAA ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. is not compliant with HIPAA regulations.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have ISO 27001 certification ?

According to Rankiteo,FUJIFILM Pharmaceuticals U.S.A., Inc. is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does FUJIFILM Pharmaceuticals U.S.A., Inc. operate in ?

FUJIFILM Pharmaceuticals U.S.A., Inc. operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does FUJIFILM Pharmaceuticals U.S.A., Inc. have ?

FUJIFILM Pharmaceuticals U.S.A., Inc. employs approximately 8 people worldwide.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. own any subsidiaries ?

FUJIFILM Pharmaceuticals U.S.A., Inc. presently has no subsidiaries across any sectors.

How many LinkedIn followers does FUJIFILM Pharmaceuticals U.S.A., Inc. have ?

FUJIFILM Pharmaceuticals U.S.A., Inc.'s official LinkedIn profile has approximately 1,355 followers.

What is the NAICS classification code for FUJIFILM Pharmaceuticals U.S.A., Inc. ?

FUJIFILM Pharmaceuticals U.S.A., Inc. is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have a Crunchbase profile ?

No, FUJIFILM Pharmaceuticals U.S.A., Inc. does not have a profile on Crunchbase.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have a LinkedIn profile ?

Yes, FUJIFILM Pharmaceuticals U.S.A., Inc. maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/fujifilm-pharma.

How many cybersecurity incidents has FUJIFILM Pharmaceuticals U.S.A., Inc. experienced ?

As of June 14, 2026, Rankiteo reports that FUJIFILM Pharmaceuticals U.S.A., Inc. has not experienced any cybersecurity incidents.

How many peer or competitor companies does FUJIFILM Pharmaceuticals U.S.A., Inc. have ?

FUJIFILM Pharmaceuticals U.S.A., Inc. has an estimated 5,686 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

FPUI

Boost Score +25 with badge (5 left)

750

/1000

Fair

775

/1000

Fair

FUJIFILM Pharmaceuticals U.S.A., Inc. Vendor Cyber Rating & Cyber Score

fujifilmpharma.com

Add Your Compliance Badge

About FUJIFILM Pharmaceuticals U.S.A., Inc. Our mission is to deliver innovative drugs to the broader population of patients worldwide at reasonable cost. FUJIFILM Pharmaceuticals U.S.A., Inc. started its operation in 2008 as FUJIFILM’s global center for new drug development. Today we are conducting multiple clinical trials in conjunction with medical institutions and industry partners that share the same vision of contributing to human health. Harnessed through FUJIFILM’s long-standing operations in photographic films, we are also providing DDS technologies to help achieve higher efficacy of treatments with less side effects. DDS technologies are expected to ensure the delivery of the therapeutic agent to the targeted area, while

FPUI A.I CyberSecurity Scoring

Scoring History

FPUI

FUJIFILM Pharmaceuticals U.S.A., Inc. CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

FPUI Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for FPUI

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for FUJIFILM Pharmaceuticals U.S.A., Inc. in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for FUJIFILM Pharmaceuticals U.S.A., Inc. in 2026.

Incident Types FPUI vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for FUJIFILM Pharmaceuticals U.S.A., Inc. in 2026.

Incident History - FPUI (X = Date, Y = Severity)

Loading…

SUBSIDIARY

FUJIFILM Pharmaceuticals U.S.A., Inc. Subsidiaries

Parent Company

FPUI

Pharmaceutical Manufacturing

Website: https://www.fujifilmpharma.com/?utm_source=LinkedIn&utm_medium=company_page&utm_campaign=visit_website

Company Size: 2-10 employees

No subsidiary data available for this company.

Loading…

FUJIFILM Pharmaceuticals U.S.A., Inc. Similar Companies

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

EMS

cb ems.com.br

Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Novo Nordisk

novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Loading…

NEWS

FUJIFILM Pharmaceuticals U.S.A., Inc. CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

April 28, 2025 07:00 AM

Regeneron expands US manufacturing with $3B Fujifilm partnership

The company has started a supply partnership with Fujifilm Diosynth Biotechnologies valued at more than $3 billion.

Read Article

June 30, 2020 02:29 AM

Careers

Learn more about careers at Fujifilm, a globally recognized leader with more than 90 years of history in innovation and technology.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-12175

SUMMARY

A vulnerability was detected in CodeAstro Student Attendance Management System 1.0. Impacted is an unknown function of the file /attendance-php/Admin/createStudents.php. Performing a manipulation of the argument admissionNumber results in sql injection. Remote exploitation of the attack is possible. The exploit is now public and may be used.

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 4.7)

cvss2

Base Score: 5.8

Complexity: LOW

AV:N/AC:L/Au:M/C:P/I:P/A:P

cvss3

Base Score: 4.7

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

1.2

REFERENCES

CVE-2026-12174

SUMMARY

A security vulnerability has been detected in D-Link DCS-935L 1.10.01. This issue affects the function snprintf of the file /web/cgi-bin/greece/rhea of the component HTTP Handler. Such manipulation of the argument data leads to format string. The attack may be launched remotely. The exploit has been disclosed publicly and may be used.

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 8.8)

cvss2

Base Score: 9.0

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 7.4

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

CVE-2026-12183

SUMMARY

Nefteprodukttekhnika BUK TS-G Gas Station Automation System 2.9.1 through 2.10.2 on Linux contains an Improper Authentication vulnerability (CWE-287) in the system configuration module. The /php/ajax-login.php endpoint returns userid=1 (administrator) in response to any HTTP POST request that supplies arbitrary credentials (e.g., action=dologin&login=<any_value>&pwd=<any_value>), and subsequent privileged endpoints under /php/ajax-main.php and /modules/* do not validate a server-side session. A remote unauthenticated attacker can invoke any administrative action exposed by the configuration module, including reading and modifying user rules, fuel tank gauges, fuel dispensers, relays, cash registers, bank terminals, fuel cards, price and customer displays, cash collection, and pricing rules.

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:L/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-6428

SUMMARY

SQL Injection in reports/catalogue_out.pl in Koha Community Koha through 22.11.37, 23.x, 24.x before 24.11.16, 25.05.x before 25.05.11, 25.11.x before 25.11.05, 26.05.x before 26.05.01, and 26.11.x before 26.11.00 allows an authenticated staff user with the Reports module flag to read arbitrary data from the Koha application database via the Filter URL parameter when the Criteria parameter matches /branchcode/. The vulnerable sink in sub calculate concatenates the unmodified Filter request parameter directly into a LIKE clause of the auxiliary $strsth2 statement and executes it via DBI without bound parameters: my $f = @$filters[0]; $f =~ s/\*/%/g; $strsth2 .= " AND $column LIKE '$f' "; This enables error-based SQL injection (e.g., via EXTRACTVALUE) and full read access to sensitive tables including borrowers (password hashes, 2FA secrets, PII), borrower_password_recovery, api_keys, and sessions. Proof of concept (error-based, single request): GET /cgi-bin/koha/reports/catalogue_out.pl?do_it=1&output=screen&Limit=10&Criteria=branchcode&Filter=x'+AND+EXTRACTVALUE(1,CONCAT(0x7e,VERSION(),0x7c,USER(),0x7c,DATABASE(),0x7e))--+- Cookie: CGISESSID=<LIBRARIAN_SESSION> The response body contains the DBI exception leaking the MariaDB version, database user, client IP, and database name, after which arbitrary data can be paged out using LIMIT n,1 / SUBSTRING(...). The vulnerable sink was introduced in commit 6bb77ae3e4 (2008-07-09); CVE-2015-4633 patched the same class in sibling files but did not generalise the fix to reports/catalogue_out.pl. Fixed in Koha 22.11.38, 24.11.16, 25.05.11, 25.11.05, 26.05.01, and 26.11.00 by replacing the raw concatenation with a parameterised placeholder.

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 7.6)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:N/A:P

cvss3

Base Score: 7.6

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:L/A:L

cvss4

Base Score: 5.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:L/UI:N/VC:H/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:Y/R:X/V:C/RE:X/U:Amber

Impact Score

4.7

Exploitability

2.8

REFERENCES

CVE-2026-5513

SUMMARY

The Online Scheduling and Appointment Booking System – Bookly plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the 'bookly-customer-full-name' cookie in versions up to, and including, 27.2 due to insufficient input sanitization and output escaping. This makes it possible for unauthenticated attackers to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page. Exploitation requires 'Remember personal information in cookies' setting to be enabled (disabled by default).

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 7.2)

cvss3

Base Score: 7.2

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:L/I:L/A:N

Impact Score

2.7

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…